Application

15386723 · BIOMARKER PROFILES FOR PREDICTING OUTCOMES OF CANCER THERAPY WITH ERBB3 INHIBITORS AND/OR CHEMOTHERAPIES

Filed 2016-12-21 · Abandoned The official file ↗ · Art unit 1642 · Examiner Nelson B Moseley II Easy · CPC C07K 16/2863 · Merrimack Pharmaceuticals, Inc. · NELSON MULLINS RILEY & SCARBOROUGH LLP/MERRIMACK

Office actions

first was Restriction requirement

RCEs

no appeal

To first action

15.7 mo

to disposition 28.7 mo

Statutes raised

103 DP

1 actions read

Unlock the prosecution timelineIncluded in Pro, from $29 a month. Cancel any time.